ClinicalTrials.gg
CompletedNCT03889912Updated Jan 21, 2026

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

A Phase 1 interventional study of Cemiplimab in Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma, sponsored by Regeneron Pharmaceuticals. Completed at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
97
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Enrollment
38th of 139
97 · median 40
Started
2019
with 8 others
Phase 1
36 of 171
4 open now
Registered
106th of 171
by date
Lead sponsor
4 of 171
Regeneron Pharmaceuticals

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 38th largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2019, is one of 36 in phase 1, and was the 106th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC).

The aim of the study is to evaluate the safety and tolerability (how your body reacts to the drug) of cemiplimab (also known as REGN2810).

The first part of the study tested several different doses of cemiplimab given weekly for 12 weeks.

The study is also looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • To see effect of cemiplimab on the tumor
  • How much study drug is in the blood at different times
03

Conditions studied

  • Cutaneous Squamous Cell Carcinoma
  • Basal Cell Carcinoma

Browse trials for

Keywords

  • CSCC
  • BCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Dose Escalation: History of recurrent resectable CSCC or BCC (Cohort C and I only) that satisfies conditions as defined in the protocol
  2. Patients must have in the index lesion, defined as 1-2 cm in the longest diameter
  3. (ECOG) performance status ≤1

Key Exclusion Criteria

  1. Ongoing or recent (within 5 years) evidence of significant disease that required treatment with systemic treatments, which may suggest risk for immune-mediated adverse events (imAEs)
  2. Prior treatment with an agent that blocks the programmed cell death 1 ()/ programmed cell death 1 ligand (PD-L1) pathway.
  3. Prior treatment with other systemic immune modulating agent as defined in the protocol
  4. M1 or N1, N2 (a, b, or c), or N3 CSCC or BCC. Patients with history of CSCC (distant or nodal), or metastatic BCC (distant or nodal) are excluded unless the disease-free interval is at least 3 years
  5. Concurrent , other than those with negligible risk of metastasis or death. Patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL), are excluded.
  6. Patients with a history of solid organ transplant
  7. Has received a Coronavirus induced disease of 2019 (COVID-19) vaccination (initial series and booster) within 1 week of planned start of study medication

Note: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Cemiplimab

    Three dose cohorts are planned and will follow a 3 + 3 dose-escalation design with cohort expansion. After completion of the above, three additional cohorts (A, B and C) of patients will be evaluated. Cohorts D, H and I may open after completion of Cohort B. Note: Cohort E through G will not be opened for participation.

    Drug: Cemiplimab

Interventions

  • Each patient will receive intralesional injections of cemiplimab every week (QW), or at less frequent dosing into the lesion at the assigned dose level for 3-12 weeks prior to scheduled surgery

    Also known as: REGN2810, Libtayo

06

What researchers measure

Primary outcomes

  1. Incidence, nature, and severity of dose limiting toxicities (DLTs) (if any) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) v5

    Dose levels 1-3

    Time frame: From the first dose through day 28

  2. Incidence, nature, and severity of treatment-emergent adverse events (TEAEs) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) v5

    Dose levels 1-3

    Time frame: From the first dose to 90 days after the last dose

  3. Incidence and severity of TEAEs graded according to the NCI CTCAE v5

    Time frame: From the first dose up to 90 days after the last dose

  4. The incidence and severity of injection site reactions (ISRs)

    Time frame: From the first dose to 90 days after the last dose

Secondary outcomes

  1. Objective response rate (ORR) of index lesion

    Determined by the investigator using the modified World Health Organization (WHO) criteria

    Time frame: At baseline and at Week 13

  2. Pathologic complete response rate (or end of treatment biopsies, for patients who decline surgery) in index lesion

    Time frame: At time of surgery

  3. Major pathologic response rate (or end of treatment biopsies, for patients who decline surgery) in index lesion

    Time frame: At time of surgery

  4. Cemiplimab concentration in serum over time

    Time frame: From the first dose up to 90 days after the last dose

  5. Incidence of anti-drug antibody (ADA) titers for cemiplimab

    Time frame: Up to 90 days after last dose

  6. Selection of the recommended dose of cemiplimab for further study based on clinical and pharmacokinetic (PK) observations

    The determination of the phase 2 recommended dose will be based primarily on clinical safety observations, according to the dose escalation scheme.

    Time frame: Up to 90 days after last dose

07

Study locations

18 sites
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006, United States
  • TCR Medical Corporation
    San Diego, California 92123, United States
  • Dermatology Associates of the Palm Beaches
    Delray Beach, Florida 33445, United States
  • MetroDerm
    Atlanta, Georgia 30342, United States
  • Northeast Dermatology Associates
    Beverly, Massachusetts 01915, United States
  • Rochester Dermatologic Surgery, P.C.
    Victor, New York 14564, United States
  • Duke Cancer Center
    Durham, North Carolina 27710, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
  • Princess Alexandra Hospital
    Brisbane, Queensland 4102, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Alfred Health
    Melbourne, Victoria 3004, Australia
  • Fremantle Dermatology
    Fremantle, Western Australia 6160, Australia
  • Radboud University Medical Center
    Nijmegen, Gelderland 6500 HB, Netherlands
  • Maastricht University Medical Center
    Maastricht, Limburg 6202 AZ, Netherlands
  • The Netherlands Cancer Institute - Antoni van Leeuwenhoek
    Amsterdam, North Holland 1066 CX, Netherlands
  • University of Groningen, University Medical Centre Groningen
    Groningen, 9700 RB, Netherlands
  • Erasmus MC
    Rotterdam, 3015 GD, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Nov 2025, 79 months.

Of 28 phase 1 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 51. This study's 79 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2019
First posted
Mar 26, 2019
StartActual
Apr 11, 2019
Primary completionActual
Nov 13, 2025
CompletionActual
Dec 10, 2025
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03889912
Responsible party
Sponsor
First posted
Mar 26, 2019
Start date
Apr 11, 2019
Primary completion
Nov 13, 2025
Completion
Dec 10, 2025
Last update
Jan 21, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion